2000
Advanced Glycosylation Endproducts and Diabetic Vascular Disease
Bucala R. Advanced Glycosylation Endproducts and Diabetic Vascular Disease. Developments In Cardiovascular Medicine 2000, 224: 287-303. DOI: 10.1007/978-1-4615-4649-8_15.Peer-Reviewed Original ResearchDiabetic vascular diseaseVascular diseaseAtherosclerotic vascular diseaseClinical pharmacological studiesProgressive vasculopathyOverall morbidityMicrovascular diseaseAnatomic typesPersistent hyperglycemiaDiabetic complicationsEtiologic roleAdvanced glycosylation endproductsBiochemical abnormalitiesDiabetic sequelaeNon-enzymatic glycosylationPharmacological studiesUnderlying causeDiseaseCapillary bedComplicationsBasic laboratoryVasculopathyMorbidityHyperglycemiaRetinopathy
1996
An agent cleaving glucose-derived protein crosslinks in vitro and in vivo
Vasan S, Zhang X, Zhang X, Kapurniotu A, Bernhagen J, Teichberg S, Basgen J, Wagle D, Shih D, Terlecky I, Bucala R, Cerami A, Egan J, Ulrich P. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 1996, 382: 275-278. PMID: 8717046, DOI: 10.1038/382275a0.Peer-Reviewed Original ResearchConceptsAGE crosslinksAdvanced glycation pathwayLow-density lipoproteinPotential therapeutic approachPotential pharmacological strategiesFormation of AGEsReactive α-dicarbonylsPharmacological strategiesGlycation pathwayTherapeutic approachesAdvanced glycationNon-enzymatic glycosylationCollagen crosslinkingNormal agingN-phenacylthiazolium bromideConnective tissueCellular receptorsAgeGlycationTissueProtein crosslinksPost-translational modification processMatrix componentsVivo pointAccelerated rate